Heping Zhao1, Hui Wang2, Hui Li3, Weiran Zheng1, Tanwei Yuan1, Anping Feng1, Dan Luo1, Yuqing Hu1, Yinghui Sun1, Yi-Fan Lin1, Yiguo Zhou1, Ganfeng Luo1, Qiaoli Peng2, Jianzhou Yang4, Junjie Xu5, Huachun Zou1,6,7. 1. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, PR China. 2. National Clinical Research Center for Infectious Diseases, The Third People' S Hospital of Shenzhen and the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, China. 3. Shizhong District Center for Disease Control and Prevention, Jinan, China. 4. Department of Preventive Medicine, Changzhi Medical College, Changzhi, Shanxi, China. 5. Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, China. 6. Kirby Institute, University of New South Wales, Sydney, Australia. 7. School of Public Health, Shanghai Jiao Tong University, Shanghai, PR China.
Abstract
OBJECTIVES: The coronavirus disease-2019 (COVID-19) pandemic continues to ravage the world. People living with HIV (PLHIV) are one of the most vulnerable groups. This study aims to identify the factors associated with the uptake and adverse reactions of COVID-19 vaccination. METHODS: We recruited PLHIV in China by convenience sampling between 7 and 23 February 2021. Participants were asked to complete an online questionnaire. Chi-squared test and multivariable logistic regression were used to assess factors associated with vaccine uptake. RESULTS: A total of 527 vaccinated and 1091 unvaccinated PLHIV were recruited. Individuals who had a higher education, engaged in occupations with a higher risk of COVID-19 infection, received influenza or pneumonia vaccine in the past 3 years (5.40, 3.36-8.77), believed in the effectiveness of vaccines (3.01, 2.20-4.12), and received media information regarding COVID-19 vaccine (2.23, 1.61-3.11), were more likely to be vaccinated. Concerning about adverse reactions (0.31, 0.22-0.44), negative impact on the progression of HIV/AIDS (0.36, 0.26-0.50) or antiretroviral therapy (ART) (0.61, 0.44-0.85), disclosure of HIV infection status (0.69, 0.49-0.96), comorbidities (0.33, 0.22-0.47), being unmarried (0.43, 0.28-0.66) and older age were negatively associated with vaccination. Of the 527 vaccinated PLHIV, 155 (29.4%) PLHIV reported adverse reactions, with pain at the injection site being the most common (18.2%). CONCLUSIONS: PLHIV, who are concerned about adverse reactions, negative impact on ART outcome and disclosure of HIV infection status, were less likely to adopt COVID-19 vaccination. To increase vaccination coverage among PLHIV, health-care professionals should emphasize the benefits and necessity of vaccination and provide consultancy regarding adverse reactions.
OBJECTIVES: The coronavirus disease-2019 (COVID-19) pandemic continues to ravage the world. People living with HIV (PLHIV) are one of the most vulnerable groups. This study aims to identify the factors associated with the uptake and adverse reactions of COVID-19 vaccination. METHODS: We recruited PLHIV in China by convenience sampling between 7 and 23 February 2021. Participants were asked to complete an online questionnaire. Chi-squared test and multivariable logistic regression were used to assess factors associated with vaccine uptake. RESULTS: A total of 527 vaccinated and 1091 unvaccinated PLHIV were recruited. Individuals who had a higher education, engaged in occupations with a higher risk of COVID-19 infection, received influenza or pneumonia vaccine in the past 3 years (5.40, 3.36-8.77), believed in the effectiveness of vaccines (3.01, 2.20-4.12), and received media information regarding COVID-19 vaccine (2.23, 1.61-3.11), were more likely to be vaccinated. Concerning about adverse reactions (0.31, 0.22-0.44), negative impact on the progression of HIV/AIDS (0.36, 0.26-0.50) or antiretroviral therapy (ART) (0.61, 0.44-0.85), disclosure of HIV infection status (0.69, 0.49-0.96), comorbidities (0.33, 0.22-0.47), being unmarried (0.43, 0.28-0.66) and older age were negatively associated with vaccination. Of the 527 vaccinated PLHIV, 155 (29.4%) PLHIV reported adverse reactions, with pain at the injection site being the most common (18.2%). CONCLUSIONS: PLHIV, who are concerned about adverse reactions, negative impact on ART outcome and disclosure of HIV infection status, were less likely to adopt COVID-19 vaccination. To increase vaccination coverage among PLHIV, health-care professionals should emphasize the benefits and necessity of vaccination and provide consultancy regarding adverse reactions.
Authors: Sélim Benjamin Guessoum; Jonathan Lachal; Rahmeth Radjack; Emilie Carretier; Sevan Minassian; Laelia Benoit; Marie Rose Moro Journal: Psychiatry Res Date: 2020-06-29 Impact factor: 3.222
Authors: Kimberly A Fisher; Sarah J Bloomstone; Jeremy Walder; Sybil Crawford; Hassan Fouayzi; Kathleen M Mazor Journal: Ann Intern Med Date: 2020-09-04 Impact factor: 25.391
Authors: Victor Grech; Michael Borg; Charmaine Gauci; Christopher Barbara; Simon Attard Montalto; Steve Agius; Celia Falzon Journal: Early Hum Dev Date: 2020-10-01 Impact factor: 2.079
Authors: Harapan Harapan; Abram L Wagner; Amanda Yufika; Wira Winardi; Samsul Anwar; Alex Kurniawan Gan; Abdul Malik Setiawan; Yogambigai Rajamoorthy; Hizir Sofyan; Mudatsir Mudatsir Journal: Front Public Health Date: 2020-07-14